Here, we found that knockdown of cht4 significantly suppressed the level of released UDP in the presence of trametinib in RAP tumours (Fig. 3H), suggesting that canonical NF-κB activity also influences trametinib response by regulating Pi3k-mediated glucose uptake. The gene discussed is NFKB1; the disease is neoplasm.